Literature DB >> 8807402

Cellular drug efflux and reversal therapy of cancer.

P W Wigler1.   

Abstract

A prevalent form of multidrug resistance (MDR) in cancer cells is caused by an ATP-dependent drug efflux pump; this pump catalyzes the rapid exit of cytotoxic chemotherapy drugs from the cells. The Michaelis equation can be used to describe drug efflux through the MDR pump at a low drug substrate concentration [S]. The inhibition mechanism of an MDR reversal agent can be characterized when two different values of [S] are used to determine two values for the half-inhibition of efflux through the pump (I50). The reaction is noncompetitive when the two values of I50 are identical; the reaction is competitive when an increase in [S] produces a significant increase in the value of I50. The I50 has been determined for several different reversal agents with the substrate rhodamine 123. The inhibition potency observed is: cyclosporin A > DMDP > amiodarone > verapamil > quinidine > quinine > propranolol. Chemotherapy drugs that are potent inhibitors of the MDR pump could be used for the treatment of MDR neoplasia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807402     DOI: 10.1007/bf02110701

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  23 in total

1.  Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo.

Authors:  P Genne; M T Dimanche-Boitrel; R Y Mauvernay; G Gutierrez; O Duchamp; J M Petit; F Martin; B Chauffert
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

2.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.

Authors:  K Dano
Journal:  Biochim Biophys Acta       Date:  1973-10-25

Review 3.  Using purified P-glycoprotein to understand multidrug resistance.

Authors:  A B Shapiro; V Ling
Journal:  J Bioenerg Biomembr       Date:  1995-02       Impact factor: 2.945

4.  Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

Authors:  E Solary; D Caillot; B Chauffert; R O Casasnovas; M Dumas; M Maynadie; H Guy
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

5.  Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

Authors:  B L Lum; S Kaubisch; A M Yahanda; K M Adler; L Jew; M N Ehsan; N A Brophy; J Halsey; M P Gosland; B I Sikic
Journal:  J Clin Oncol       Date:  1992-10       Impact factor: 44.544

Review 6.  Clinical trials of agents that reverse multidrug resistance. A literature review.

Authors:  M Raderer; W Scheithauer
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

7.  Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration.

Authors:  G D Pennock; W S Dalton; W R Roeske; C P Appleton; K Mosley; P Plezia; T P Miller; S E Salmon
Journal:  J Natl Cancer Inst       Date:  1991-01-16       Impact factor: 13.506

8.  Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.

Authors:  D Boesch; K Muller; A Pourtier-Manzanedo; F Loor
Journal:  Exp Cell Res       Date:  1991-09       Impact factor: 3.905

9.  Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines.

Authors:  K N Thimmaiah; J K Horton; X D Qian; W T Beck; J A Houghton; P J Houghton
Journal:  Cancer Commun       Date:  1990

10.  Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines.

Authors:  C E Cass; A Janowska-Wieczorek; M A Lynch; H Sheinin; A A Hindenburg; W T Beck
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

View more
  7 in total

1.  Evaluation of an in vitro coculture model for the blood-brain barrier: comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources.

Authors:  J L Scism; D A Laska; J W Horn; J L Gimple; S E Pratt; R L Shepard; A H Dantzig; S A Wrighton
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

2.  Multidrug resistance protein 1 (MRP1) in rabbit conjunctival epithelial cells: its effect on drug efflux and its regulation by adenoviral infection.

Authors:  Johnny J Yang; David K Ann; Ram Kannan; Vincent H L Lee
Journal:  Pharm Res       Date:  2007-04-03       Impact factor: 4.200

3.  Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation.

Authors:  In Young Kim; You Jung Kang; Mi Jin Yoon; Eun Hee Kim; Seung U Kim; Taeg Kyu Kwon; In Ah Kim; Kyeong Sook Choi
Journal:  Neuro Oncol       Date:  2011-02-03       Impact factor: 12.300

4.  Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers.

Authors:  J J Yang; K J Kim; V H Lee
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

5.  Effect of transporters on the secretion of phytochemicals by the roots of Arabidopsis thaliana.

Authors:  Victor M Loyola-Vargas; Corey D Broeckling; Dayakar Badri; Jorge M Vivanco
Journal:  Planta       Date:  2006-07-26       Impact factor: 4.116

6.  Vanadium elicitation of Trifolium pratense L. cell culture and possible pathways of produced isoflavones transport across the plasma membrane.

Authors:  Jan Kubes; Milan Skalicky; Lenka Tumova; Jan Martin; Vaclav Hejnak; Jaroslava Martinkova
Journal:  Plant Cell Rep       Date:  2019-02-15       Impact factor: 4.570

7.  Is the Mitochondrial Membrane Potential (∆Ψ) Correctly Assessed? Intracellular and Intramitochondrial Modifications of the ∆Ψ Probe, Rhodamine 123.

Authors:  Ljubava D Zorova; Evgeniya A Demchenko; Galina A Korshunova; Vadim N Tashlitsky; Savva D Zorov; Nadezda V Andrianova; Vasily A Popkov; Valentina A Babenko; Irina B Pevzner; Denis N Silachev; Egor Y Plotnikov; Dmitry B Zorov
Journal:  Int J Mol Sci       Date:  2022-01-01       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.